Diabetes and bone-metabolic research unit, Department of Endocrinology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Diabetes and bone-metabolic research unit, Department of Endocrinology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Cancer Treat Res Commun. 2021;28:100426. doi: 10.1016/j.ctarc.2021.100426. Epub 2021 Jun 17.
Chemotherapy-induced peripheral neuropathy (CIPN) is a recognized adverse effect of standard (neo)adjuvant chemotherapy in breast cancer (BC) treatment. However, there is no consensus on a validated method for assessing CIPN. Heart rate variability (HRV) and vibration perception threshold (VPT) could be used as objective measures to describe CIPN. The aim of this pilot study was to investigate whether subjectively reported CIPN was associated with altered HRV and VPT in BC patients.
We performed a cross-sectional pilot study evaluating 30 BCE patients previously treated with chemotherapy, 26 BCE patients who did not receive chemotherapy, and 22 controls without breast cancer. Self-reported CIPN was registered for the BC patients. All participants were subjected to multi-frequency vibration analyses to determine VPT along with short ECG measurements to determine HRV measures.
Self-reported CIPN was registered in 14 (46.6%) BC patients treated with chemotherapy. The VPT at 64 Hz (P = 0.022) and mean HR (P = 0.022) were significantly higher and the HRV measures SDNN (P = 0.023), RMSSD (P = 0.007), LF (P = 0.050) and HF (P = 0.045) were significantly lower in BC patients reporting CIPN compared to controls when adjusted for age. VPT at 64 Hz and 125 Hz were significantly higher in BC patients not reporting CIPN compared to controls when adjusted for age.
We found elevated VPT and mean HR along with decreased HRV parameters in 14 BCE patients reporting CIPN. These findings support the need for further investigation into whether HRV and vibration analysis could contribute to an objective assessment of CIPN.
化疗引起的周围神经病（CIPN）是乳腺癌（BC）治疗中标准（新）辅助化疗的一种公认的不良反应。然而，对于 CIPN 的评估方法尚未达成共识。心率变异性（HRV）和振动感知阈值（VPT）可作为描述 CIPN 的客观指标。本研究的目的是探讨 BC 患者中主观报告的 CIPN 是否与 HRV 和 VPT 的改变相关。
我们进行了一项横断面研究，评估了 30 例接受化疗的 BC 患者、26 例未接受化疗的 BC 患者和 22 例无乳腺癌的对照者。对接受化疗的 BC 患者进行主观 CIPN 登记。所有参与者均接受多频振动分析以确定 VPT，并进行短 ECG 测量以确定 HRV 测量。
14 例（46.6%）接受化疗的 BC 患者报告了 CIPN。与对照组相比，报告 CIPN 的 BC 患者的 64 Hz 处 VPT（P=0.022）和平均 HR（P=0.022）显著升高，且 HRV 指标 SDNN（P=0.023）、RMSSD（P=0.007）、LF（P=0.050）和 HF（P=0.045）显著降低，校正年龄后差异有统计学意义。校正年龄后，报告无 CIPN 的 BC 患者的 64 Hz 和 125 Hz 处 VPT 明显高于对照组。
我们发现 14 例报告 CIPN 的 BC 患者的 VPT 和平均 HR 升高，HRV 指标降低。这些发现支持进一步研究 HRV 和振动分析是否有助于对 CIPN 进行客观评估的必要性。
